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Abstract
Background: Mucosal immune surveillance is thought to be largely achieved through uptake by specialized
epithelial M cells. We recently identified Claudin 4 as an M cell target receptor and developed a Claudin 4
targeting peptide (CPE) that can mediate uptake of nanoparticles through Nasal Associated Lymphoid Tissue
(NALT) M cells.
Methods: Recombinant influenza hemagglutinin (HA) and a version with the CPE peptide at the C-terminal end
was used to immunize mice by the intranasal route along with a single dose of cholera toxin as an adjuvant.
Serum and mucosal IgG and IgA responses were tested for reactivity to HA.
Results: We found that the recombinant HA was immunogenic on intranasal administration, and inclusion of the
CPE targeting peptide induced higher mucosal IgA responses. This mucosal administration also induced systemic
serum IgG responses with Th2 skewing, but targeting did not enhance IgG responses, suggesting that the IgG
response to mucosal immunization is independent of the effects of CPE M cell targeting.
Conclusions: M cell targeting mediated by a Claudin 4-specific targeting peptide can enhance mucosal IgA
responses above the response to non-targeted mucosal antigen. Since Claudin 4 has also been found to be
regulated in human Peyer’s patch M cells, the CPE targeting peptide could be a reasonable platform delivery
technology for mucosal vaccination.
Background
Most infectious agents enter the body through mucosal
surfaces such as the intestine or airways. Protective
immune responses induced by such infections involve
both cellular immune responses and systemic IgG, but
at mucosal surfaces secretory IgA provides the most
effective protection. Studies have indicated that IgA
responses are dependent on immune responses in
mucosal lymphoid tissues such as intestinal Peyer’s
patches and Nasal Associated Lymphoid Tissues
(NALT) or tonsils [1-4], where epithelial M cells acquire
and transport antigens to underlying lymphoid tissue.
Unfortunately, conventional vaccines rely instead on
injected antigens, which induce IgG but not IgA. Live
attenuated virus vaccines such as cold-adapted influenza
(e.g., FluMist
®), or oral polio vaccine can provide better
mucosal immunity, but these are a greater challenge to
develop, and they require an expensive cold chain that
complicates delivery in developing countries.
Vaccination at mucosal surfaces is a strategy that can
help overcome the limitations of injected vaccines (nee-
dle disposal, trained medical staff required to administer
the vaccine), but also to provide the benefit of mucosal
IgA responses. Progress with this strategy has been
made in animal studies using two distinct approaches
that could be described as bioengineering versus immu-
nological. In typical bioengineering approaches, vaccine
antigens are encapsulated in polymer nanoparticles to
package and protect the antigen (reviewed in [5]); the
particles are administered in an aerosol suspension for
inhalation, or as a liquid suspension for intranasal instil-
lation. Here, it is assumed that M cells will non-specifi-
cally acquire the encapsulated antigens from the lumen
and initiate mucosal immune responses. However, anti-
gen can also be acquired by dendritic cells in the muco-
sal epithelium [6,7] and drain into other lymphoid
tissues, so mucosal IgA responses are not always effi-
ciently induced.
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cal approaches are based on targeting antigen delivery
to M cells for specific uptake; direct targeting should
provide greater control over the induced immune
response than unregulated transport to draining lymph
nodes. In animal models, targeting to M cells has been
successful in inducing mucosal IgA responses. M cell
targeting was achieved using a variety of ligands, includ-
ing lectins or antibodies specific to a fucose moiety pre-
sented at the surface of mouse (but not human) M cells
[8-10], RGD peptides to bind exposed integrins [11],
and a Reovirus sigma protein specific for JAM-A
[12-14]. Challenges still remain, such as the identifica-
tion of M cell target receptors that will reliably work in
humans, and the identification of an effective mucosal
adjuvant. Indeed, in the absence of an effective adjuvant,
M cell targeting in mice has been found to be very
effective in inducing immunological tolerance instead of
immunity [12,13].
We previously identified the tight junction protein
Claudin 4 as a candidate M cell endocytosis receptor
[15-17]. Though Claudin 4 is normally found in tight
junctions, it was also found redistributed into the cyto-
plasm of mouse and human M cells and appears to be
part of the particle endocytosis machinery. To test the
potential of Claudin 4 targeting, we developed a peptide
derived from the c-terminal domain of the Clostridium
perfringens enterotoxin (CPE), which binds to the sec-
ond external domain of Claudin 4 [18,19]. Using fluores-
cently labeled microparticles and polymer nanoparticles
displaying CPE or fusion proteins with CPE, we demon-
strated that the CPE peptide retains Claudin 4 binding
[20] and mediates enhanced uptake by M cells in vivo
[21,22]. In addition, CD137 mutant mice that lack M
cell function failed to take up Claudin 4-targeted parti-
cles, confirming the M cell-dependent uptake [23].
Thus, using the CPE peptide, M cell targeting of muco-
sal vaccines might be possible in humans.
In the present study, we tested the mucosal immune
response to engineered vaccine fusion proteins incorpor-
ating antigen and the CPE M cell targeting peptide. We
report here that with an intranasal administration proto-
col, M cell targeted fusion proteins are effective in
enhancing secretory IgA responses along with a systemic
serum Th2-skewed IgG response.
Methods
Recombinant antigens
Soluble HA [24] and fusions with fibritin [25], a c-term-
inal flagellin and/or CPE30 were designed as His-tagged
proteins, and were produced using a Baculovirus expres-
sion kit (Invitrogen) in which cloned DNA was trans-
fected into insect SF21 or SF9 cells grown in HyClone
SFX-Insect media (Thermo). The insect cells that
secrete the protein were then grown at controlled 27°C
and the supernatant harvested after incubation. The
insect culture media was filtered before purification.
Western blot (Invitrogen) was used to verify protein
expression and quality before precipitating the media
with 80% saturated ammonium sulfate (Fisher). After 2
hours of precipitation at 4°C, protein was centrifuged at
13,000 rpm for 30 minutes to obtain a pellet for proces-
sing. The resuspended protein was dialyzed overnight in
a PBS 1x solution before binding to HisPur resin
(Thermo Scientific) for 2 hours. After washing, the pro-
tein was then eluted from resin using increased concen-
trations of imidazole. Resulting elutant was then
dialyzed again in a solution of 0.1X PBS/9 mM HEPES
pH 7.4 containing 0.05% Tween-20 (Fisher) before con-
centrating down to a desired level. Final western blots
and Coomassie (Pierce) stained gels were run on each
protein to insure quality while concentration was mea-
sured using a spectrophotometer and BSA standards.
For studies on protein-peptide conjugates, CPE30 pep-
tide was conjugated to HA antigen using a CPE30 pep-
tide synthesized with a c-terminal GGGGSGGGGS
linker. This peptide was thenc h e m i c a l l yl i n k e dt oH A
at a 10:1 peptide:HA protein ratio, using EDC/Sulfo-
NHS (Pierce) activated peptides to link to available
amine groups on the HA protein.
Immunization
BALB/c mice were maintained under Specific Pathogen
Free colony conditions at the UC Riverside vivarium. All
procedures were performed in accordance with institu-
tional and NIH guidelines. Immunization was performed
by instillation of vaccine protein solutions intranasally
into anesthetized mice. A volume of 10 microliters was
instilled into each nostril (total 20 microliters per
mouse). Serum titers were assayed from peripheral
blood collected by retro-orbital puncture at the time
points indicated. For fecal antibody analysis, dry fecal
pellets were weighed, and extracted in a proportionate
amount of extraction buffer (1 ml PBS with 0.1 mg/ml
trypsin inhibitor per 100 mg fecal pellet). After incuba-
tion and centrifugation, 400 microliters of supernatant
was mixed with 100 microliters glycerol/1 mM PMSF
for storage. Broncho-Alveolar Lavage was taken by
flushing lungs with 1.0 ml PBS. In all experimental
g r o u p s ,f i v em i c ew e r eu s e dp e rg r o u p .M i c ew e r e
humanely killed under anesthesia at the conclusion of
the experiment.
Elisa
Black flat-bottom plates (Costar) were coated with
recombinant HA or synthetic CPE peptide prepared as
described at 10 ug/ml in Coating Buffer (25 mM
Na2CO3,7 5m MN a H C O 3, pH 9.5). Plates were washed
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mM KCl, 0.1% Tween 20). using a Biotek ELx405 Auto-
mated Plate Washer. Plates were blocked with 3% nor-
mal goat serum in 1X PBS, then washed as before.
Samples were diluted in blocking buffer, (1:2000 for
serum or 1:10 for Feces and BAL), then serially two-
fold, and added to the coated and blocked plate in tripli-
cate. After washing, detection was performed with either
Rat anti-mouse IgA-AP (Southern Biotech), Goat anti-
mouse IgG-AP (Southern Biotech), diluted 1:1000 and
1:2000, respectively, in 1X TBST. For IgG isotype analy-
sis, detection was performed using Goat anti-mouse
IgG1-AP (Southern Biotech) or Goat anti-mouse IgG2a-
AP (Southern Biotech), diluted 1:2000, in 1X TBST. For
final development, 10 mM 4-MUP (Molecular Probes)
in DMSO diluted 1:25 in substrate buffer (50 mM
K2CO3 2m MM g C l 2, pH 9.8) was added. Fluorescence
was detected 90 minutes later at ex 360/em 460 on
Molecular Devices SpectraMax M2e plate reader.
Statistical analysis
Except when noted, ELISA fluorescence values were
shown after background signal (equivalent dilution of
preimmune sample) was subtracted. As noted in the
text, analysis of the ELISA titers was performed by tak-
ing fluorescence values in the linear range of the titra-
tion curve. Statistical comparisons (five mice per group
in all studies) were performed using a one-tailed Mann-
Whitney test (Prism, GraphPad Software), on the ratio-
nale that a non-parametric test would best measure the
consistent effect of the specific vaccine formulations (i.
e., addition of the CPE targeting peptide), though similar
results were obtained using a t-test.
Results
Vaccination with CPE conjugated to HA
To test the ability of CPE-mediated M cell targeting to
induce mucosal immunity, we chemically conjugated the
Claudin 4-targeting CPE peptide to recombinant influ-
enza hemagglutinin (HA; extracellular domain only,
truncated at the transmembrane domain - aa 1-528
[24]), and delivered this antigen intranasally along with
cholera toxin in the first dose as an adjuvant. The con-
jugation of the peptide was accomplished by synthesiz-
ing the CPE peptide with a c-terminal linker peptide,
and then conjugating this to the HA protein with amide
linkages to available lysines. At the conjugation ratio
used in this study, there were approximately ten CPE
peptides conjugated per trimeric HA complex (or ~3
CPE peptides per monomer). We used a three dose pro-
tocol with 1 microgram cholera holotoxin in the first
dose as an adjuvant, and 20 micrograms antigen per
dose (Figure 1A). The response to a lower dose (2
microgram per dose) was very low (not shown), while
the response to the high dose was robust, so it is likely
that the chemical conjugation had detrimental effects on
the antigenicity of the recombinant HA protein.
Figure 1B shows ELISA results for serum, lung
Broncho-Alveolar Lavage (BAL), and extracts from fecal
pellets IgA responses to HA. The full titration curves
showed that the serum IgA response to HA conjugated
Figure 1 Immunization with chemical conjugation of CPE to
HA antigen. Basic protocol using HA antigen chemically
conjugated to the CPE targeting peptide, showing induction of
both systemic serum and mucosal antibody responses. A,
Immunization time line. B, ELISA results, showing fluorescence units
of anti-HA response at specified dilutions.
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However, since endpoint titer calculations could be vari-
able, we chose a point in the titration showing a rela-
tively linear titration in response, and used those values
to perform direct comparisons among groups for statis-
tical tests.
HA-CPE fusion protein vaccine
To simplify the production of the vaccine antigen, we
developed expression constructs in which the CPE pep-
tide is linked at the c-terminal end of a recombinant
fusion protein. Since the influenza hemagglutinin is nor-
mally present on the virus particle as a trimer, we
included a trimerization peptide from fibritin [25] to
stabilize the HA trimer. To separate the functional
domains, a peptide linker sequence
(GGGGSGGGGSGGGGS) was included. The final pro-
tein (Figure 2A) therefore had the structure: [HA] -
linker - [trimerization peptide] - linker - [His tag] - lin-
ker - [CPE]. For simplicity, this protein will be referred
to as HA-CPE, while the control lacking the CPE pep-
tide domain will be referred to as HA. Figure 2B shows
non-denaturing Coomassie gel of the purified protein,
and blots showing that the purified protein had intact
His tag (not shown) and HA determinants, both detect-
able by Western blot. In these non-denaturing gels the
molecular weight markers are not as reliable, but the tri-
meric complex was still clearly evident as a band at a
higher molecular weight. The control HA antigen used
was the same except for the absence of the c-terminal
linker and CPE domain.
In this experiment (Figure 3A), a four dose protocol
was used; 2 micrograms of the recombinant antigen was
given intranasally, with 1 microgram cholera holotoxin
in the first dose. Three boosters with antigen alone fol-
lowed, given in weekly intervals. One week after the last
dose, samples were collected from serum lung lavage,
and fecal pellets. In this experiment (Figure 3B; shown
with background subtracted), the two groups of animals
produced similar levels of IgG anti-HA responses in
serum, but the targeted HA-CPE antigen induced a sig-
nificantly higher IgA response in both serum and fecal
pellets. The BAL showed similar responses to both anti-
gens though the mean response to targeted vaccine was
higher. Thus, with similar recombinant protein antigens,
the presence of the M cell targeting peptide CPE
induced stronger IgA responses in both serum and the
mucosal tissues. Despite the enhanced IgA response to
HA, we were unable to detect any antibody response to
the CPE peptide, when tested against synthetic CPE
peptide bound directly to ELISA plates (not shown).
Persistence of mucosal IgA response
To assess the persistence of mucosal IgA responses
using this vaccine in a four week protocol, mice were
tested at 4 weeks after the first dose (Figure 4A) then
tested a second time, 14 weeks after the initial dose
(Figure 4A). In both groups, significant responses to HA
were detected at the 14 week time point. The increased
serum IgA response to targeted antigen seen at 4 weeks
a f t e rt h ef i r s td o s e( F i g u r e4 B )w a sl e s se v i d e n ta t1 4
weeks (Figure 4C), but an increased BAL IgA response
was present at the 14 week time point. Thus, a persis-
tent mucosal response to intranasal immunization was
detected after 14 weeks, with some enhancement
induced by the targeted vaccination.
Similar results were found when a weekly three dose
protocol (Figure 5A) was assessed for evidence for
enhanced mucosal responses. In this case serum IgA
was not significantly enhanced at the early time point
(four weeks - one week after the last dose; Figure 5B)
and the targeted vaccine showed the best mucosal
Figure 2 Recombinant HA trimeric fusion protein. Development
of a hybrid recombinant HA fusion protein vaccine incorporating
the CPE targeting peptide. The recombinant HA protein forms
trimeric complexes detectable in non-denaturing gels. A, Schematic
of the recombinant fusion, as detailed in the text. B, Non-denaturing
gels with Coomassie stain and Western blot for HA, showing
trimeric and monomeric forms of the protein. Note that in non-
denaturing gels, the protein molecular weight markers are not as
accurate as in denaturing gels, so the molecular weight
comparisons are only relative.
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response showed persistence through the 14 week time
point (Figure 5C). Fecal responses were not significantly
higher in the group given the targeted vaccine at the 14
week time point (not shown), but as with the four dose
protocol, lung bronchoalveolar lavage did show slightly
enhanced responses in the group given the targeted vac-
cine (Figure 5C). Notably, as with the short term stu-
dies, the 14 week serum IgG responses were similarly
strong in all groups, whether given non-targeted or
targeted vaccine, or whether using a three dose or four
dose protocol.
Mucosal administration and Ig isotypes
While targeted vaccine showed enhanced mucosal IgA
responses, mucosal administration of non-targeted vac-
cine also induced some, albeit lower, mucosal IgA
responses. By contrast, the serum IgG response to HA
was generally equivalent whether targeted or not. Thus,
intranasal administration and M cell targeting both con-
tributed more to the induction of the enhanced mucosal
IgA rather than to the systemic IgG response. To con-
firm that the administration route rather than the anti-
gen itself was most important to IgA induction, we
compared intranasal immunization with a conventional
subcutaneous immunization given as a mixture with
alum (Figure 6A).
Mice were given three weekly intranasal doses of 2
microgram HA-CPE with cholera holotoxin adjuvant in
the first dose, or a single subcutaneous injection of 20
micrograms HA in alum. On the fourth week, both
groups of mice showed similar serum IgG responses
(Figure 6B). However, in mucosal tissues such as BAL,
significant IgA anti-HA responses were present in mice
given intranasal HA-CPE, while the HA/alum immu-
nized mice had nearly undetectable IgA responses. Con-
sistent with clinical responses to injected influenza
vaccines, some mice did have low but detectable IgG
responses in BAL (not shown).
The regulation of B cell isotype switching is deter-
mined by a combination of tissue specific factors (e.g.,
APRIL, TGF-beta) [26-29]. In the case of T cell depen-
dent antibody responses, cytokines supporting IgA
responses are predominantly associated with Th2 cells,
also associated with a stronger IgG1 isotype response
compared to an IgG2a isotype [30,31]. In confirmation
of this Th2 dominance in the response to mucosal
immunization, we found that the anti-HA titers in the
serum showed an IgG1 dominance over IgG2a, esti-
mated to be at least 10:1 (Figure 6C). This Th2 domi-
nance may be a direct consequence of the mucosal
immunization route [3], or the use of cholera toxin as
the adjuvant [32,33]. Despite a similar Th2 dominance
induced by alum adjuvant (Figure 6C), it clearly was not
dependent on association mucosal IgA responses (Figure
6B). Moreover, the IgG titers were similar, though the
antigen dose administered by the subcutaneous route
(20 ug) was much higher than the total dose given by
the intranasal route (6 ug). While it is also possible that
the HA antigen is also predisposed toward Th2
responses, other forms of HA can induce Th1/IgG2a
responses in mice [34].
Figure 3 Immune response to Recombinant fusion protein.
Recombinant protein vaccine and a basic four week intranasal
immunization protocol, showing enhanced IgA responses by CPE
targeting. Systemic serum IgG responses were also induced, without
improvement by CPE targeting. A, Immunization protocol. B, ELISA
results, showing increased IgA response to HA-CPE protein.
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The studies presented here extend our studies on M cell
particle uptake showing that the Claudin 4 targeting
CPE peptide can effectively mediate M cell uptake in
both the NALT and intestinal Peyer’s patches. In these
studies, the enhanced uptake mediated specific enhance-
ment of mucosal IgA responses, though the enhance-
ment was not uniformly robust. Similar mouse M cell
targeting of soluble proteins have been reported by
others, both for inducing T and B cell immune
responses including induction of secretory IgA [8-11,14]
and for induction of mucosal tolerance [12,13]. A recent
study successfully used the much larger toxin subunit
C-CPE for mucosal vaccination [35], though in that
study the authors expected the effect to depend on the
C-CPE gaining entry past epithelial tight junctions. By
contrast, our studies showed that our shorter CPE pep-
tides do not disrupt epithelial tight junctions in vivo,
and instead mediate uptake through M cells [20,21].
This approach using short CPE peptides is an advance
over other strategies, as the targeting ligand has no risk
of disrupting mucosal epithelium, and it can be used in
humans (many other targeting approaches only apply to
mouse M cells). While the short targeting peptide has
only moderate affinity for the target receptor it does not
appear to induce blocking antibodies, so it should be
useful in multiple dosing strategies or for multiple vac-
cines. Our previous studies showed uptake of nanoparti-
cles by M cells, but the present studies show that this
can also be applied to the delivery of proteins in a phy-
siological solution.
Interestingly, M cell targeting by CPE had little enhan-
cing influence on serum IgG responses, suggesting that
it may be more important in focusing antigen to muco-
sal lymphoid tissues for IgA induction rather than
affecting the overall efficiency of antigen delivery. Since
IgA isotype switching is thought to be mainly dependent
on mucosal lymphoid tissues such as Peyer’s patch, Iso-
lated Lymphoid Follicles, and NALT, the utility of M
Figure 4 Persistence of response to recombinant protein vaccine, four dose protocol. After an initial four week course of immunization,
mice were rested for ten weeks for later assay. Results showed persistence of both the antibody response and evidence for enhanced IgA
response when CPE targeting was used. A, Immunization protocol. B, Response 4 weeks after first dose. C, Response 14 weeks after first dose.
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settings where secretory IgA is more desirable as the
best form of protective immunity. In addition to local
protection of mucosal epithelium from invasive
microbes, targeted immunization for IgA responses can
provide secondary benefits for mothers immunized
against mucosal pathogens; IgA in the milk can help
protect nursing infants [36]. Finally, mucosal vaccination
in general also has clear value for its ease of administra-
tion, and efficiency in inducing persistent mucosal and
systemic IgG responses on a per-dose basis.
Conclusions
The present results extend our previous findings that a
Claudin 4 targeting peptide can mediate enhance muco-
sal M cell uptake. Here, we found that fusion proteins
incorporating both a vaccine antigen and a short Clau-
din 4-binding peptide can enhance mucosal IgA
responses to intranasal administration. In addition, the
intranasal route of vaccine administration appeared to
be more efficient on a per-dose basis in inducing sys-
temic IgG responses as compared to subcutaneous
administration. Thus, mucosal vaccination strategies
Figure 5 Persistence of response to recombinant protein vaccine, three dose protocol. Using an initial three week course of immunization
followed by an eleven week rest period, persistent antibody responses were evident, along with enhanced IgA responses to the CPE targeted
vaccine. A, Immunization protocol. B, Response 3 weeks after first dose. C, Response 14 weeks after first dose.
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specific for known human M cell targets should have
promise in clinical applications.
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